Αρχική World News VA Study Finds No Disparities in Prostate Cancer Deaths with Equal Access...

VA Study Finds No Disparities in Prostate Cancer Deaths with Equal Access to Care

, by NCI Staff

A nurse showing an African American man his test results.

A study of men treated in the Veterans Affairs health care system supports the hypothesis that differences in access to health care are a cause of prostate cancer disparities.

Credit: iStock

In the United States, African American men are more likely to be diagnosed with prostate cancer than white men, tend to be diagnosed at younger ages and with more advanced disease, and are more than twice as likely to die of the disease. The reasons for these disparities have not been clear.

“There is a perception among some in the medical community that prostate cancer is inherently more aggressive among African American men, and that there’s nothing we can do about” disparities in deaths from the disease, said Brent Rose, M.D., a radiation oncologist at the University of California at San Diego. But some studies have pointed to differences in access to health care as a cause of the disparities, and a new study by Dr. Rose and his colleagues supports that hypothesis.

The team found that among patients treated in the US Department of Veterans Affairs (VA) health care system—where all patients have equal access to care—African American men did not appear to have more-aggressive prostate cancer at the time of diagnosis or a higher death rate from the disease than non-Hispanic white men.

“Well-designed observational studies like this one are important for helping us to better understand the importance of access to care,” said Janet de Moor, Ph.D., M.P.H, of the Healthcare Delivery Research Program in NCI’s Division of Cancer Control and Population Sciences, who was not involved with the study.

“This study, while imperfect, definitely adds to our understanding of racial disparities in prostate cancer outcomes,” agreed David Penson, M.D., M.P.H., a urologic oncologist and health services researcher at Vanderbilt University, who also was not involved in the study.

The study, published January 27 in Cancer, suggests that providing equal access to health care could be important for eliminating or reducing disparities in prostate cancer deaths, Dr. de Moor said.

African American Men Fared as Well as or Slightly Better than White Men

Dr. Rose’s team analyzed information on more than 60,000 men with prostate cancer from a large, nationwide database with medical and treatment information on more than 20 million veterans treated in the VA system. The men had been diagnosed with prostate cancer between 2000 and 2015. Of these men, 30.3% were African American and 69.7% were non-Hispanic white.

The median follow-up time for African American and non-Hispanic white men was approximately 5.8 and 5.9 years, respectively. African American men were more likely than the non-Hispanic white men to live in areas with a lower median income and lower high school graduation rates, the research team reported.

In the VA system, the team found, African American men did not experience delays in diagnosis or care for their prostate cancer compared with non-Hispanic white men, and they were no more likely to be diagnosed with more-advanced or more-aggressive prostate cancers. African American men also were no more likely than non-Hispanic white men to die of their disease.

In fact, African American men in the VA system were slightly less likely than non-Hispanic white men to die from prostate cancer within 10 years after diagnosis: The 10-year death rate from prostate cancer was 4.4% for African American men and 5.1% for non-Hispanic white men.

This lower death rate was seen even after the researchers adjusted for factors that could potentially account for the difference, such as severity of disease at diagnosis, type of treatment received, and other illnesses.

The reason for the difference in prostate cancer deaths remains unclear, and “would be interesting to explore more fully,” Dr. de Moor said.

Interestingly, African American men in the VA system also were less likely than non-Hispanic white men to die of noncancer causes, Dr. Penson said.

A “Compelling” Study, Though Questions Remain

Key strengths of this study include the large number of patients, the fact that everyone in the VA health care system has equal access to care, and the racially diverse patient population, Drs. Penson and de Moor both said. In addition, Dr. Penson said, “the comprehensive nature of the VA’s electronic medical records and the reliability of the system to capture [patient] survival outcomes strengthen the findings considerably.”

However, as the authors noted, the study also has important limitations. Because it was a retrospective observational analysis—that is, it looked back in time at patient medical records—the study cannot show conclusively that equal access to good medical care is the reason racial disparities were not seen in the VA patients. Additionally, Dr. de Moor said, “there may be some differences between people treated at the VA and [people in the general population].”  

And while Dr. Penson called the study “quite compelling,” he noted that other factors, such as patients leaving the VA system to get care elsewhere and the lower mortality rate from causes other than cancer among African American veterans, could have affected the results.

Some studies have suggested that biological differences may also play a role in prostate cancer disparities, especially in the increased incidence and younger age at diagnosis in African American men.

And it’s possible, Dr. Penson said, that both biology and access to care contribute to the differences in prostate cancer outcomes that researchers have long observed. “In the end, we need to consider strategies to address disparities that account for both possibilities,” he continued.

Addressing Disparities Beyond the VA System

Numerous studies have identified access to care as a contributor to health-related disparities, including previous studies that examined disparities in prostate cancer outcomes, Dr. de Moor noted.

“The bigger issue is what can be done about it,” Dr. Penson said. Legislative solutions for increasing access to quality health care continue to be debated, he continued. “This study underscores the importance of those efforts.”

“Further research is required to look into what specifically can be done to improve care for everyone,” Dr. Rose said. “The solution is … to try to figure out what factors [in the VA system] are leading to good outcomes in African American men and how we could expand those to the broader health care community.”

To help identify those factors, Dr. Rose and his colleagues are planning further studies using additional data from the VA health system. They also intend to use the VA database to look at multiple cancer types, not just prostate cancer, to “see if preventive care, such as that provided by primary care doctors, can help reduce the rate of advanced cancers, particularly in minority communities.”



Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like

Διαβαστε Επίσης


ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...

Καρκίνος: Ευεργετική για τους καρκινοπαθείς η άσκηση

Σημαντικά ωφέλη προσφέρει η άσκηση, ακόμη και σε ασθενείς με καρκίνο. Οι περισσότεροι ασθενείς αγνοούν τα οφέλη που μπορεί να έχει γι’ αυτούς η συχνή...

Prostate Cancer

The article is provided by Scientific Communications Officer of NIPD Genetics, Ms Marina Charitou (MSc) Prostate Cancer Awareness Prostate cancer is the second most common cancer...
- Advertisment -

Ροή Ειδήσεων

News digest – ovarian cancer blood test, statins, spending review and head and neck cancer immunotherapy

Ovarian cancer blood test ‘better than previously thought’   A new investigation into an existing blood test to detect ovarian cancer has uncovered better-than-expected...

Woman with Nonverbal Autism Diagnosed with Breast Cancer After Caregiver Sister Finds Lump

Tabitha Cyrus, whose friends and family affectionately call her Taffy, was three years old when she was diagnosed with autism. Her family had anticipated...

Living With Metastatic Breast Cancer: How I Reinvented Myself

Shonte Drakeford is a 36-year-old Washington, D.C. native, nurse practitioner, United States Army wife, and German Shepherd mama. She was diagnosed with stage IV...

The Mediterranean Diet

The Mediterranean diet is a predominately plant based diet that accents omega 3 rich fish sources and whole foods that are minimally processed. Olives...

Results of Continuous vs Intermittent Dosing Schedules of BRAF/MEK Inhibitor Combination Therapy in the S1320 Study

Opposite to the initial study hypothesis, the results of the S1320 indicate that intermittent dosing of BRAF/MEK inhibitor combination did not improve progression-free survival...

FDA Approves Companion Diagnostic to Identify NTRK Fusions in Solid Tumours for Larotrectinib

On 23 October 2020, the US Food and Drug Administration (FDA) approved the next-generation sequencing (NGS)-based FoundationOne CDx test (Foundation Medicine, Inc.) as a...